| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Tigatuzumab (anti-TNFRSF10B)
CAS:918127-53-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13714
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Tigatuzumab
CAS:918127-53-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Guangzhou Hongyuan Chemical Co.,Ltd
|
| Tel: |
15817493340 |
| Email: |
981810490@qq.com |
| Products Intro: |
Product Name:Tigatuzumab
CAS:918127-53-4
Purity:95% Package:1mg;1g;100g
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Tigatuzumab
CAS:918127-53-4
Purity:95% Package:1mg/RMB 2320;5mg/RMB 6220;10mg/RMB 8380
|
|
| | Tigatuzumab Basic information |
| Product Name: | Tigatuzumab | | Synonyms: | Tigatuzumab;Research Grade Tigatuzumab (DHA29102);Research Grade Tigatuzumab;Tigatuzumab (anti-TNFRSF10B) | | CAS: | 918127-53-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tigatuzumab Structure]() |
| | Tigatuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tigatuzumab Usage And Synthesis |
| Uses | Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1]. | | in vivo | Tigatuzumab (3 mg/kg; i.v. weekly for 4 weeks) effectively represses the tumor growth in human pancreatic cancer MIA PaCa-2-RFP orthotopic mouse model[1]. | Animal Model: | Nude mice with MIA PaCa-2-RFP human pancreatic cancer cells injection[1] | | Dosage: | 3 mg/kg | | Administration: | Intravenous injection; 3 mg/kg weekly for 4 weeks | | Result: | Reduced the tumor volume and decreased the density of viable cancer cells in tumors.
|
| | References | [1] Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184. DOI:10.1016/j.canlet.2020.07.034 |
| | Tigatuzumab Preparation Products And Raw materials |
|